{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "MTD",
  "name": "Mettler-Toledo International",
  "url": "https://frontierpicks.com/dossiers/MTD/",
  "json_url": "https://frontierpicks.com/dossiers/MTD.json",
  "status": "WATCHLIST",
  "current_conviction": "MEDIUM",
  "archetype": {
    "code": "a2",
    "n": 2
  },
  "current_thesis": "Mettler-Toledo's third-quarter beat and a 2027 earnings guide above estimates support modest outperformance against the S&P 500; the fourth-quarter report, expected in early February 2027, settles whether about 5% sales growth holds.",
  "invalidation_trigger": "A daily close below $1,500, which would put the shares under their 50-day moving average and below the $1,679.08 close of 2026-11-05 before the earnings reaction; or a company report that cuts 2027 guidance of about 5% local currency sales growth and $52.50–$53.50 adjusted EPS.",
  "catalyst_date": null,
  "portfolio": null,
  "pick": null,
  "themes": [
    "medtech-diagnostics"
  ],
  "tags": [],
  "sources": [],
  "caveats": [],
  "source_links": [
    {
      "title": "METTLER TOLEDO INTERNATIONAL INC/ - Form 8-K - FY2026",
      "url": "https://www.sec.gov/Archives/edgar/data/0001037646/000103764626000072/ex-991mtd8xkq32026.htm",
      "date": "2026-11-05"
    },
    {
      "title": "Mettler-Toledo (MTD) Q3 2026 Earnings Call Transcript",
      "url": "https://www.fool.com/earnings/call-transcripts/2026/11/06/mettler-toledo-mtd-q3-2026-earnings-call-transcript/",
      "date": "2026-11-06"
    },
    {
      "title": "Mettler-Toledo International (NYSE:MTD) Stock Price Expected to Rise, Barclays Analyst Says",
      "url": "https://www.marketbeat.com/instant-alerts/analyst-mettler-toledo-international-nyse-mtd-stock-price-expected-to-rise-barclays-analyst-says-2026-11-09/",
      "date": "2026-11-09"
    },
    {
      "title": "Mettler-Toledo International (NYSE:MTD) Stock Price Target Raised at Stifel Nicolaus",
      "url": "https://www.marketbeat.com/instant-alerts/analyst-mettler-toledo-international-nyse-mtd-stock-price-target-raised-at-stifel-nicolaus-2026-11-09/",
      "date": "2026-11-09"
    },
    {
      "title": "Jefferies raises Mettler-Toledo stock price target on solid growth",
      "url": "https://za.investing.com/news/stock-market-news/jefferies-raises-mettlertoledo-stock-price-target-on-solid-growth-93CH-4559062",
      "date": "2026-11-06"
    },
    {
      "title": "Mettler-Toledo International Inc. to Host Investor Meeting",
      "url": "https://investor.mt.com/news/news-details/2026/Mettler-Toledo-International-Inc--to-Host-Investor-Meeting/default.aspx",
      "date": "2026-10-12"
    },
    {
      "title": "Mettler-Toledo International Inc. Reports Second Quarter 2026 Results",
      "url": "https://www.businesswire.com/news/home/20260730448694/en/",
      "date": "2026-07-30"
    }
  ],
  "evidence": [
    {
      "claim": "Third-quarter 2026 sales were $1.094 billion, up 6% in US dollars and local currency; adjusted EPS was $12.57, up 13% from $11.15.",
      "source": "Q3 2026 earnings release (Form 8-K, 2026-11-05)",
      "as_of": "2026-11-05"
    },
    {
      "claim": "2027 guidance calls for about 5% local currency sales growth and adjusted EPS of $52.50–$53.50; Benzinga cited a $51.76 estimate.",
      "source": "Q3 2026 earnings release (Form 8-K); Benzinga, 2026-11-05",
      "as_of": "2026-11-05"
    },
    {
      "claim": "2026 adjusted EPS guidance was raised to $47.70–$47.90 from $47.15–$47.50; 2026 sales guidance is $4.227 billion against a $4.238 billion estimate.",
      "source": "Benzinga, 2026-11-05",
      "as_of": "2026-11-05"
    },
    {
      "claim": "Management guided 2027 free cash flow of about $950 million, share repurchases of about $950 million and operating margin expansion of about 70 basis points at the midpoint.",
      "source": "Q3 2026 earnings call, 2026-11-06",
      "as_of": "2026-11-06"
    },
    {
      "claim": "Third-quarter local currency sales rose 3% in the Americas, 2% in Europe and 14% in Asia/Rest of World; China grew 13%.",
      "source": "Q3 2026 earnings release (Form 8-K); 2026-11-06 earnings call",
      "as_of": "2026-11-06"
    },
    {
      "claim": "Barclays raised its target to $1,900 from $1,700 (Overweight), Stifel to $1,900 from $1,600 (Buy), Baird to $1,815 (Neutral), JPMorgan to $1,725 from $1,550 (Neutral) and Goldman Sachs to $1,640 from $1,510.",
      "source": "Benzinga, fiscal.ai and MarketBeat, 2026-11-09",
      "as_of": "2026-11-09"
    },
    {
      "claim": "MarketBeat listed a consensus Hold rating (6 Buy, 8 Hold, 1 Sell), a $1,555.38 consensus target and a 37.38 price-to-earnings ratio.",
      "source": "MarketBeat, 2026-11-09",
      "as_of": "2026-11-09"
    },
    {
      "claim": "Eight directors received share grants of 54 to 77 shares each on 2026-11-10; no open-market purchases were reported.",
      "source": "SEC Form 4 filings, 2026-11-12",
      "as_of": "2026-11-12"
    }
  ],
  "view_changes": [],
  "frame": null,
  "filed_numbers": {
    "as_of": "2026-11-13",
    "sector": "Healthcare",
    "financials": {
      "status": "ok",
      "reason": null,
      "close_date": "2026-11-13",
      "latest_quarter": "2026-09-30",
      "figures": {
        "revenue": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-30",
              "filed": "2026-11-06",
              "restated": null,
              "value_musd": 1094.3,
              "yoy_pct": 6.3
            },
            {
              "end": "2026-06-30",
              "filed": "2026-07-31",
              "restated": null,
              "value_musd": 1027.3,
              "yoy_pct": 4.5
            },
            {
              "end": "2026-03-31",
              "filed": "2026-05-08",
              "restated": null,
              "value_musd": 947.1,
              "yoy_pct": 7.2
            },
            {
              "end": "2025-12-31",
              "filed": "2026-02-06",
              "restated": null,
              "value_musd": 1129.7,
              "yoy_pct": 8.1
            },
            {
              "end": "2025-09-30",
              "filed": "2025-11-07",
              "restated": null,
              "value_musd": 1029.7,
              "yoy_pct": 7.9
            },
            {
              "end": "2025-06-30",
              "filed": "2025-08-01",
              "restated": null,
              "value_musd": 983.2,
              "yoy_pct": 3.9
            }
          ]
        },
        "gross_margin": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-30",
              "filed": "2026-11-06",
              "restated": null,
              "pct": 59.8
            },
            {
              "end": "2026-06-30",
              "filed": "2026-07-31",
              "restated": null,
              "pct": 63.3
            },
            {
              "end": "2026-03-31",
              "filed": "2026-05-08",
              "restated": null,
              "pct": 58.7
            },
            {
              "end": "2025-12-31",
              "filed": "2026-02-06",
              "restated": null,
              "pct": 59.8
            },
            {
              "end": "2025-09-30",
              "filed": "2025-11-07",
              "restated": null,
              "pct": 59.2
            },
            {
              "end": "2025-06-30",
              "filed": "2025-08-01",
              "restated": null,
              "pct": 59
            }
          ]
        },
        "operating_margin": {
          "status": "not reported"
        },
        "pretax_income": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-06",
          "value_musd": 300.2
        },
        "net_income": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-06",
          "four_quarters_end": "2026-09-30",
          "value_musd": 246,
          "four_quarters_musd": 934.1
        },
        "operating_cash_flow": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-06",
          "first_end": "2025-12-31",
          "value_musd": 984.4
        },
        "capital_spending": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-06",
          "first_end": "2025-12-31",
          "value_musd": 113.8
        },
        "free_cash_flow": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-06",
          "first_end": "2025-12-31",
          "value_musd": 870.6
        },
        "diluted_share_change": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-06",
          "base_end": "2025-09-30",
          "pct": -2.7
        },
        "cash": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-06",
          "value_musd": 52.2
        },
        "debt": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-06",
          "value_musd": 2023.7
        },
        "net_cash": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-06",
          "value_musd": -1971.4
        },
        "deferred_revenue": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-06",
          "value_musd": 247.4,
          "yoy_pct": 5.6
        },
        "backlog": {
          "status": "not reported"
        },
        "receivables": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-06",
          "value_musd": 733.2
        },
        "inventory": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-06",
          "value_musd": 439.7
        },
        "equity": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-06",
          "value_musd": 77.7
        },
        "market_value": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-09-30",
          "basis_filed": "2026-11-06",
          "value_musd": 34587.6
        },
        "enterprise_value": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-09-30",
          "basis_filed": "2026-11-06",
          "value_musd": 36559.1
        },
        "ev_sales": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-09-30",
          "basis_filed": "2026-11-06",
          "multiple": 8.7
        },
        "ev_ebit": {
          "status": "not available"
        },
        "pe": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-09-30",
          "basis_filed": "2026-11-06",
          "multiple": 37
        },
        "pb": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-09-30",
          "basis_filed": "2026-11-06",
          "multiple": 445.4
        },
        "fcf_yield": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-09-30",
          "basis_filed": "2026-11-06",
          "pct": 2.5
        }
      }
    },
    "short_interest": {
      "status": "ok",
      "settlement": "2026-10-15",
      "published": "2026-10-26",
      "short_pct_of_outstanding": 3.31,
      "days_to_cover": 3.1,
      "change_pct": -7.2
    },
    "insiders": {
      "status": "ok",
      "as_of": "2026-11-15",
      "windows": [
        {
          "days": 90,
          "status": "ok",
          "from": "2026-08-18",
          "bought_usd": 0,
          "sold_usd": 2096663.6,
          "bought_unpriced": 0,
          "sold_unpriced": 0
        },
        {
          "days": 365,
          "status": "ok",
          "from": "2025-11-16",
          "bought_usd": 0,
          "sold_usd": 20320106.35,
          "bought_unpriced": 0,
          "sold_unpriced": 0
        }
      ]
    }
  },
  "body_markdown": "## Current Thesis\n\nMettler-Toledo's third-quarter beat and a 2027 earnings guide above estimates support modest outperformance against the S&P 500 over the next three months. The fourth-quarter report, expected in early February 2027, settles whether about 5% local currency sales growth and $52.50–$53.50 adjusted earnings per share (EPS) for 2027 hold. The rating is Medium because the business evidence is strong but the price has already run ahead of most analyst targets.\n\nThe company makes precision weighing and laboratory instruments for drug makers, chemical producers, food companies and industrial plants. Its 2026-11-05 release reported third-quarter sales of $1.094 billion, up 6% in local currency, and adjusted EPS of $12.57, up 13% from $11.15. Benzinga cited estimates of $1.071 billion and $12.09. The company raised its 2026 adjusted EPS guidance to $47.70–$47.90 from $47.15–$47.50.\n\nThe price already reflects much of this. The shares closed at $1,730.93 on 2026-11-12, above the $1,555.38 consensus target MarketBeat listed on 2026-11-09 and close to the $1,725 target JPMorgan set the same day. For the shares to keep leading, the 2027 guide has to survive the February report intact.\n\n## Bull Case\n\n- **2027 guidance starts above estimates.** The $52.50–$53.50 adjusted EPS range published on 2026-11-05 implies 10% to 12% growth, per the company. Its low end sits above the $51.76 estimate Benzinga cited that day.\n- **Cash returns are large and specific.** Chief financial officer Shawn Vadala guided 2027 free cash flow to about $950 million and share repurchases to about $950 million on the 2026-11-06 call. The company bought back $638.7 million of shares in the first nine months of 2026, per its release.\n- **Margins are still expanding.** Vadala put 2027 operating margin expansion at about 70 basis points (0.7 percentage point) at the midpoint on the 2026-11-06 call. Third-quarter adjusted EPS grew 13% on 6% sales growth.\n- **Americas sales turned positive.** Americas local currency sales rose 3% in the third quarter, per the 2026-11-05 release, after a 3% decline in the second quarter reported on 2026-07-30.\n- **Targets moved up across the board.** Jefferies raised its target to $1,930 from $1,580 on 2026-11-06, per Investing.com. Barclays raised to $1,900 from $1,700 (Overweight) and Stifel to $1,900 from $1,600 (Buy) on 2026-11-09, per MarketBeat.\n\n## Bear Case\n\n- **The price sits above the consensus target.** MarketBeat put the consensus target at $1,555.38 on 2026-11-09, with 6 Buy, 8 Hold and 1 Sell ratings. Goldman Sachs' $1,640 target and JPMorgan's $1,725 target, both set on 2026-11-09 per fiscal.ai, sit below the 2026-11-12 close of $1,730.93.\n- **The valuation is full.** MarketBeat listed a price-to-earnings ratio of 37.38 on 2026-11-09. Baird and JPMorgan both kept Neutral ratings while raising targets on 2026-11-09.\n- **Europe stays weak.** Europe's local currency sales rose 2% in the third quarter, down from 7% in the second, per the company's releases. Management guided 2027 Europe to low single digits on the 2026-11-06 call, citing energy costs and trade disputes.\n- **China growth is guided to slow sharply.** Vadala expects mid-teens China growth in the fourth quarter but mid-single digits for 2027, per the 2026-11-06 call. China grew 13% in the third quarter and drove the beat.\n- **The 2026 sales guide trails estimates.** The company set 2026 sales guidance at $4.227 billion against a $4.238 billion estimate, per Benzinga on 2026-11-05. The EPS raise came with a sales figure slightly below what analysts expected.\n\n## Setup & Price Structure\n\nThe shares closed at a record $1,762.28 on 2026-11-09, the day of the company's investor meeting, and set a 52-week intraday high of $1,806.58 on 2026-11-06, the session after the third-quarter release. They closed lower in each of the next three sessions, ending at $1,730.93 on 2026-11-12, 4.2% below that high. The close before the earnings reaction was $1,679.08 on 2026-11-05.\n\nThe three-month gain is 22.0%, measured from a $1,419.02 close on 2026-08-14. As of 2026-11-12 the 50-day moving average stood at $1,552.95 and the 200-day at $1,350.46, both in adjusted daily closes. The 52-week closing low was $1,025.53 on 2026-05-13, so the shares have climbed far from their spring trough.\n\nThe gap between the close and the 50-day average leaves room for a pullback with no change in the business. SEC Form 4 filings dated 2026-11-12 show only routine share grants of 54 to 77 shares to eight directors on 2026-11-10, with no open-market purchases. No company report is due before early February 2027.\n\n## Catalyst Calendar\n\n- **~2027-02-05 (est.):** Fourth-quarter 2026 report. It tests fourth-quarter guidance of $14.84–$15.04 adjusted EPS and mid-teens China growth, and shows whether the 2027 outlook of about 5% local currency growth and $52.50–$53.50 adjusted EPS stands.\n\n## What Would Change Our Mind\n\nA daily close below $1,500, which would put the shares under their 50-day moving average and below the $1,679.08 close of 2026-11-05 before the earnings reaction; or a company report that cuts 2027 guidance of about 5% local currency sales growth and $52.50–$53.50 adjusted EPS.\n\nThe risks this note tracks, each with what would confirm it:\n\n- The share price leaves little room for disappointment after closing above the consensus target. Confirmed by: Target cuts or downgrades following the round of raises on 2026-11-06 and 2026-11-09.\n- Europe's slowdown deepens, leaving growth dependent on Asia. Confirmed by: Europe's local currency sales flat or falling in the fourth-quarter report, after 2% growth in the third quarter and 7% in the second.\n- China growth fades faster than the mid-single-digit 2027 guide. Confirmed by: Fourth-quarter China growth well below the mid-teens management guided on 2026-11-06.\n- The Americas recovery proves brief as US pharma and industrial customers hold back capital spending. Confirmed by: Americas local currency sales falling again in the fourth-quarter report, after 3% growth in the third quarter.\n- Cash generation misses the 2027 free cash flow guide of about $950 million. Confirmed by: Full-year 2026 adjusted free cash flow below the prior year, extending the nine-month decline to $651.9 million from $689.5 million.\n\n## Correlation Notes\n\nThe shares depend on capital spending by drug makers and industrial customers. Vadala called pharma the standout of the third quarter on the 2026-11-06 call. Asia and Rest of World sales grew 14% in local currency, against 3% in the Americas and 2% in Europe, which makes China demand and European industrial activity the main swing factors. Third-quarter sales grew 6% in both US dollars and local currency, so currency had no net effect in that quarter. MarketBeat listed the stock's beta, its sensitivity to moves in the broad market, at 1.16 on 2026-11-09.",
  "first_seen": "2026-11-10",
  "last_analyzed": "2026-11-12T23:03:41+00:00",
  "last_synthesized": "2026-11-12",
  "date_modified": "2026-11-12",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}